75 related articles for article (PubMed ID: 2517029)
1. Structure-activity relationship between prostacyclin and its platelet receptor. Correlation of structure change and the platelet activity.
Tsai AL; Wu KK
Eicosanoids; 1989; 2(3):131-43. PubMed ID: 2517029
[TBL] [Abstract][Full Text] [Related]
2. Diphenylmethylazine prostanoids with prostacyclin-like actions on human platelets.
Jones RL; Wilson NH; Marr CG; Muir G; Armstrong RA
J Lipid Mediat; 1993; 6(1-3):405-10. PubMed ID: 8357998
[TBL] [Abstract][Full Text] [Related]
3. (5Z)-carbacyclin displays agonist-antagonist properties on prostacyclin-receptors in platelets and vascular myocytes.
Corsini A; Oliva D; Folco GC; Giovanazzi S; Noe' MA; Fumagalli R; Nicosia S
Biomed Biochim Acta; 1988; 47(10-11):S104-7. PubMed ID: 3073757
[TBL] [Abstract][Full Text] [Related]
4. The platelet rebound phenomenon during PGI2-infusion occurs at the receptor level.
Steurer G; Fitscha P; Sinzinger H
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):435-8. PubMed ID: 2465947
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry.
Eggerman TL; Harker LA; Andersen NH; Wilson CH
Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888
[No Abstract] [Full Text] [Related]
6. Refractoriness of platelets to prostaglandins after infusion in rabbits.
Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E
J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the biological activity of azoprostanoids in human platelets.
Gorman RR; Shebuski RJ; Aiken JW; Bundy GL
Fed Proc; 1981 May; 40(7):1997-2000. PubMed ID: 7014259
[TBL] [Abstract][Full Text] [Related]
8. Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5- oxazolyl]phenoxy]acetic acid.
Meanwell NA; Romine JL; Rosenfeld MJ; Martin SW; Trehan AK; Wright JJ; Malley MF; Gougoutas JZ; Brassard CL; Buchanan JO
J Med Chem; 1993 Nov; 36(24):3884-903. PubMed ID: 7504734
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship (SAR) among prostacyclin (PGI2) analogues.
Kovács G; Székely I; Stadler I; Körmöczy P
Acta Physiol Hung; 1984; 64(3-4):225-30. PubMed ID: 6397963
[TBL] [Abstract][Full Text] [Related]
10. Human prostacyclin platelet receptors in diabetes mellitus.
Modesti PA; Fortini A; Gensini GF; Vanni D; Prisco D; Abbate R
Thromb Res; 1991 Sep; 63(5):541-8. PubMed ID: 1755006
[TBL] [Abstract][Full Text] [Related]
11. PGI2 receptors in vasculature and platelets: 5Z-carbacyclin discriminates between them.
Nicosia S; Oliva D; Noè MA; Corsini A; Folco GC; Fumagalli R
Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():474-8. PubMed ID: 2959100
[No Abstract] [Full Text] [Related]
12. Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids.
Sharif NA; Crider JY; Xu SX; Williams GW
J Pharmacol Exp Ther; 2000 May; 293(2):321-8. PubMed ID: 10772998
[TBL] [Abstract][Full Text] [Related]
13. Nonprostanoid prostacyclin mimetics. 4. Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid substituted alpha to the oxazole ring.
Meanwell NA; Rosenfeld MJ; Wright JJ; Brassard CL; Buchanan JO; Federici ME; Fleming JS; Gamberdella M; Hartl KS; Zavoico GB
J Med Chem; 1993 Nov; 36(24):3871-83. PubMed ID: 8254619
[TBL] [Abstract][Full Text] [Related]
14. 7-Oxabicyclo[2.2.1]heptane analogs as modulators of the thromboxane A2 and prostacyclin receptors.
Sprague PW; Heikes JE; Harris DN; Greenberg R
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():337-43. PubMed ID: 6303073
[No Abstract] [Full Text] [Related]
15. The antiplatelet activity of immobilized prostacyclin.
Ebert CD; Lee ES; Kim SW
J Biomed Mater Res; 1982 Sep; 16(5):629-38. PubMed ID: 6752148
[TBL] [Abstract][Full Text] [Related]
16. Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets.
Kajikawa N; Nogimori K; Murata T; Nishio S; Uchiyama S
Arzneimittelforschung; 1989 Apr; 39(4):495-9. PubMed ID: 2665758
[TBL] [Abstract][Full Text] [Related]
17. Heterologous desensitization of platelet adenosine (A2) responses by iloprost.
MacDermot J; Wilkins AJ; Edwards RJ
Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():479-81. PubMed ID: 2444081
[No Abstract] [Full Text] [Related]
18. Structure-activity relationship study on the 6-membered heteroaromatic ring system of diphenylpyrazine-type prostacyclin receptor agonists.
Asaki T; Hamamoto T; Sugiyama Y; Kuwano K; Kuwabara K; Niwa T
Bioorg Med Chem Lett; 2007 Dec; 17(23):6588-92. PubMed ID: 17920266
[TBL] [Abstract][Full Text] [Related]
19. The antiaggregatory effectiveness of PGI2 and its binding to specific platelet receptors. A comparative study.
Jaschonek K; Renn W; Weisenberger H
Prog Clin Biol Res; 1987; 242():13-8. PubMed ID: 3313410
[No Abstract] [Full Text] [Related]
20. PGE1 but not PGI2 desensitizes the PGI2 receptor-adenylate cyclase complex in human foreskin fibroblasts.
Gorman RR; Hopkins NK
Adv Prostaglandin Thromboxane Res; 1980; 8():1717-21. PubMed ID: 6246790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
